Gabapentin Capsule
Product Images NDC 60760-818

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-818). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba (Gabapentin 60760 818 60)

Gabapentin 100 mg capsules label showing a 60 count package from St. Mary's Medical Park Pharmacy. The label includes the NDC 60760-818-60, manufactured by Sridhes Pharma Science Limited in India. It indicates storage at controlled room temperature (15°-30° C) and states 'USE AS DIRECTED' with Rx only designation.*

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing the formula for calculating creatinine clearance (CLCr), which includes variables for age, weight, serum creatinine, and an adjustment factor for female patients. The formula is presented in a mathematical expression format.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure diagram of gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H). This structural formula represents the active ingredient gabapentin.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph depicting the mean pain score over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to week 8, with labeled 4-week dose titration and fixed dose periods. The y-axis measures mean pain score from 0 to 10. Two lines represent placebo and Gabapentin, showing a decrease in pain score for Gabapentin compared to placebo over time.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph depicting mean pain scores over a 7-week period. The horizontal axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. Three lines show results for placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. Pain scores decrease over time, with both Gabapentin doses showing greater reductions compared to placebo.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses in two studies. Study 1 shows 12% response for PBO and 29% for GBP 3600 mg. Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance markers indicate p-values below 0.01 and 0.001 for Gabapentin doses.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing percentage difference versus daily dose (mg) in three studies labeled a, b, and c. The x-axis shows daily dose amounts of 600, 900, 1200, and 1800 mg, while the y-axis shows percentage difference from 2% to 22%. Data points are marked with distinct shapes and labeled by study. The graph visually compares outcomes for each study across varying doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.